YEATS-domain inhibition improved ALS-related outcomes in flies and protected stressed human neurons
Original source
Context-dependent YEATS-domain inhibition enhances neuronal resilience and improves ALS phenotypes. (opens in a new tab)Compass summarised this from the study's abstract.
Study details
- Studied in
- Human
Population inferred from the title and abstract by Compass.
In laboratory studies, blocking the ENL/AF9 YEATS domain improved survival and stress tolerance in fruit-fly models of some ALS-related mutations. The inhibitor SR-0813 also improved survival in cultured human neurons exposed to several stresses, especially endoplasmic reticulum stress. Effects varied by disease model, and some chronic aggregation or mitochondrial-stress models worsened or showed little benefit.
Why this matters
The findings identify ENL/AF9 stress-response signaling as a possible research target for ALS and related conditions. They do not show that SR-0813 benefits people with ALS or provide a treatment change, because the work was conducted in flies and cultured human neurons rather than in a clinical trial.
Limitations and context
This was a laboratory study using fruit flies and cultured human neurons, not people. Benefits were model-dependent, and the source does not report a clinical trial or establish safety, dosing, or effectiveness in humans. The study was published as a journal article, but the supplied source does not provide details on sample sizes or independent replication.